-
Survivor Profile
The Gift of MusicA self-taught musician takes what he has learned from his experience with kidney cancer to entertain, teach and inspire.
by Jenny Song
-
Forward Look
Breast Density MattersBreast cancer risk factor may be overlooked.
by Kendall K. Morgan
-
Q&A
Trial GuideResearcher Tom Marsilje is helping fellow colorectal cancer patients sort through clinical trials.
by Kate Yandell
-
Going Off-LabelPhysicians are legally permitted to prescribe drugs approved for one purpose to be used for another, a practice called off-label prescribing. The rise of targeted therapies and immunotherapies is creating new challenges for navigating off-label options.
by Kate Yandell
-
Forward Look
Tackling Drug ResistanceResearchers are studing new ways to keep treatments working longer.
by Stephen Ornes
-
Revised Prostate Cancer Screening Guidelines ProposedThe U.S. Preventive Services Task Force suggests an individualized approach to prostate cancer screening.
-
-
Forward Look
Advances in Treating Non–Small Cell Lung CancerExpanded approvals in 2016 increase options.
by Jennifer L.W. Fink
-
Yesterday & Today
TV’s Family ManMichael Landon, best known for his roles on Little House on the Prairie and Bonanza, created and starred in programs that portrayed family values with authenticity and humor.
by Marci A. Landsmann
-
Survivor Profile
Putting Her Armor OnAn acute myeloid leukemia survivor and former TV news reporter finds a new reason to help others improve their health.
by Jennifer Walker
A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
-
AACR IO: Revolutionizing Treatment through ImmunotherapyThe AACR’s immuno-oncology meeting brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
